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TRAF2 in osteotropic breast cancer 
cells enhances skeletal tumour 
growth and promotes osteolysis
Prabha Peramuhendige1,2, Silvia Marino1,2, Ryan T. Bishop1, Daniëlle de Ridder1, Asim 
Khogeer1,2, Isabella Baldini3, Mattia Capulli3, Nadia Rucci3 & Aymen I. Idris  1,2
NFκB plays an important role in inflammation and bone remodelling. Tumour necrosis factor receptor 
associated factor 2 (TRAF2), a key component of NFκB signalling, has been identified as an oncogene, 
but its role in the regulation of breast cancer osteolytic metastasis remains unknown. Here, we report 
that stable overexpression of TRAF2 in parental and osteotropic sub-clones of human MDA-MB-231 
(MDA-231) breast cancer cells increased cell growth and motility in vitro, whereas TRAF2 knockdown 
was inhibitory. In vivo, TRAF2 overexpression in the parental MDA-231-P cells enhanced tumour growth 
after orthotopic injection into the mammary fat pad of mice but failed to promote the metastasis of 
these cells to bone. In contrast, overexpression of TRAF2 in osteotropic MDA-231-BT cells increased 
skeletal tumour growth, enhanced osteoclast formation and worsened osteolytic bone loss after intra-
tibial injection in mice. Mechanistic and functional studies in osteotropic MDA-231-BT and osteoclasts 
revealed that upregulation of TRAF2 increased the ability of osteotropic MDA-231-BT cells to migrate 
and to enhance osteoclastogenesis by a mechanism dependent, at least in part, on NFκB activation. 
Thus, the TRAF2/NFκB axis is implicated in the regulation of skeletal tumour burden and osteolysis 
associated with advanced breast cancer.
TNF receptor associated factor (TRAF) super family of adaptor proteins plays an important role in inflammation, 
breast cancer and bone remodelling1–4. Of the 7 known members of the TRAF superfamily, TRAF2 is a common 
target for pro-inflammatory and tumour-derived factors such as tumour necrosis factor alpha (TNFα), interleu-
kin 1 (IL-1), receptor activator of NFκB ligand (RANKL), transforming growth factor beta (TGFβ), and cluster 
of differentiation 40 ligand (CD40L)2,3,5–9. Binding of these mediators to their receptors initiates the recruitment 
of TRAF2 to their respective receptors2,6,7,10–14 and triggers the activation of multiple intracellular signalling cas-
cades including the canonical NFκB pathway2,5–8,15,16. TRAF2 also undergoes phosphorylation, protein–protein 
interaction with DNA and other TRAF molecules and functions as an E3 ubiquitin ligase to activate downstream 
events essential for NFκB activation3,15–19.
The TRAF2/NFκB signalling pathway plays a critical role in lactating mammary-gland development and 
breast cancer. Elevated TRAF2 expression correlates with breast cancer cell invasion and metastasis in patients8,20. 
In addition, TRAF2 regulates the activity of various breast cancer oncogenes, and inhibition of TRAF2 has been 
associated with reduction in mammary tumour growth6,10,12,17,19,21–23. Recently, TRAF2 has been described as an 
NFκB activating oncogene in breast epithelial cells6,7. Breast cancer cells in bone (osteotropic) cause bone damage 
by producing osteolytic factors that enhance osteoclastogenesis and inhibit osteoblast differentiation via NFκB 
activation24–26. TRAF2-mediated NFκB activation plays a key role in the regulation of bone remodelling, and 
numerous studies have demonstrated that inflammation-induced TRAF2 activation causes bone loss by increas-
ing osteoclast formation and inhibiting osteoblast survival2,4,26–28. However, the role of TRAF2 in the development 
of breast cancer bone metastasis and its contribution to osteoclast and osteoblast changes associated with these 
metastases has not been investigated.
In the present study, we showed that cancer-specific TRAF2 expression contributes to breast cancer-induced 
osteolysis. Our in vivo, ex vivo and in vitro investigation showed that TRAF2 expression in the osteotropic 
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MDA-231 human breast cancer cells increases tumour cell growth in bone, and enhances the ability of these cells 
to induce osteoclast formation and to cause osteolysis in mice. Thus, therapeutic targeting of TRAF2/NFκB sig-
nalling may be of value in protecting the skeleton from osteolytic bone damage associated with advanced breast 
cancer.
Results
Upregulation of TRAF2 enhances parental tumour cell growth in vitro and in vivo. TRAF2 
enhances mammary tumour growth7, and we have observed that TRAF2 expression is upregulated in the human 
osteotropic MDA-231 breast cancer cell line when compared to their parental control (Fig. S1A). In view of this, 
we hypothesized that TRAF2 is implicated in bone metastasis, skeletal tumour growth and osteolysis associated 
with advanced breast cancer. We stably overexpressed (Fig. S1B,C) and knocked down (Fig. S1D,E) TRAF2 in the 
parental MDA-231-P and their osteotropic sub-clone MDA-231-BT (Fig. S1B–E), and assessed the growth and 
metastatic behaviour of these cells in vitro, ex vivo and in vivo. First, we confirmed that TRAF2 overexpression 
in parental MDA-231-P enhanced migration within 6 hours, whereas its knockdown in these cells was inhibi-
tory (Fig. 1A,B). Overexpression of TRAF2 also increased the invasion of parental MDA-231-P after 48 hours 
(Fig. 1C,D). Of note, TRAF2 overexpression or knockdown had no effect on the viability of parental MDA-231-P 
(Fig. 1E). Next, we evaluated the mammary tumour growth and bone metastasis of parental MDA-231-P in mice 
after orthotopic injection (Fig. 1F,H). Overexpression of TRAF2 enhanced MDA-231-P growth in the mammary 
fat pads (Fig. 1G) but failed to cause osteolytic lesions in mice (Fig. 1H). We also failed to detect any MDA-231-P 
cells expressing green fluorescent protein in bone aspirates ex vivo (data not shown).
Upregulation of TRAF2 enhances breast cancer-induced osteolysis in vivo. To test if TRAF2 is 
implicated in the regulation of osteolytic activity of breast cancer cells, we assessed skeletal tumour growth and 
osteolysis in mice after intra-tibial injection of the osteotropic sub-clone MDA-231-BT. Overexpression of TRAF2 
in these cells markedly increased tumour growth in bone (Fig. 2A,B) and enhanced their ability to cause osteol-
ysis (Fig. 2C,E). As shown in Fig. 2, panel D, detailed microCT analysis of bone samples from this experiment 
revealed significant reduction in trabecular bone volume (BV/TV) that is accompanied by reduced trabecular 
number and thickness, increased trabecular separation and decreased trabecular connectivity (increased trabec-
ular pattern factor and SMI). We also detected significant increase in cortical porosity (Fig. 2E) whereas cortical 
area and thickness remained unchanged (data not shown).
Cancer-specific TRAF2 regulates osteotropic breast cancer – bone cell crosstalk. Breast cancer 
cells contribute to osteolysis through secretion of pro-inflammatory factors4. To explore the role of TRAF2 in this 
process, we took advantage of an in vivo supracalvarial injection and ex-vivo calvarial osteoblast organ models to 
assess osteolysis in response to MDA-231-BT conditioned medium in adult immuno-competent mice (unlike the 
MDA-231-BT nude mouse model described above) (Fig. 3A,D). Conditioned medium from MDA-231-BT cells 
overexpressing TRAF2 (MDA-231-BT-T2OE) induced osteolytic bone damage in calvarial bone in vivo (Fig. 3B,C) 
and ex vivo (Fig. 3E,F) that is characterized by significant loss in bone volume (p < 0.01). Histomorphometric 
analysis of the calvarial bone from the organ culture showed that conditioned medium from TRAF2 overexpress-
ing cells increased osteoclast number (Fig. 3G, left panel) without affecting the number of osteoblasts (Fig. 3G, 
right panel). Next, we employed a quantitative proteomic approach to identify the tumour-derived factor(s) 
responsible. Analysis of protein level of human cytokines and chemokines in conditioned medium revealed that 
TRAF2 overexpression in the osteotropic MDA-231-BT-T2OE is associated with upregulation of a total of 48 
secreted proteins in the conditioned medium (Fig. 3G). The identified proteins are common tumour-derived 
factors that have previously been found to be involved in the regulation of inflammation, angiogenesis, innate 
immunity and tumorigenesis (Fig. 3G and Table S1). Further evaluation of the role of these proteins in breast 
cancer, osteoclastogenesis and/or osteoblast differentiation revealed a subset of 21 proteins that are likely to be 
implicated in the regulation of the TRAF2-driven breast cancer-induced osteoclast and osteoblast changes that 
we have observed in our models (Fig. 3H and Table S2).
Cancer-specific TRAF2 regulates osteoblast and osteoclast changes associated with breast 
cancer. Previous studies have shown that TRAF2 expression in bone cells plays an important role in oste-
oclast differentiation and osteoblast apoptosis. Here, we carried out in vitro functional studies to examine the 
effects of knockdown and overexpression of cancer-specific TRAF2 on osteoclast and osteoblast changes associ-
ated with breast cancer. These experiments showed that TRAF2 overexpression significantly increased the abil-
ity of osteotropic MDA-231-BT cells (Fig. 4A) and their conditioned medium (20% v/v, Fig. 4B) to enhance 
RANKL-induced osteoclast formation in bone marrow cultures, whereas TRAF2 knockdown in these cells was 
inhibitory (Fig. 4A–C). Exposure of mouse primary osteoblasts and the human osteoblast-like cells Saos-2 cells to 
conditioned medium from the osteotropic MDA-231-BT cells overexpressing TRAF2 for 2 (mouse osteoblasts) or 
12 (human Saos-2) days had no effect on osteoblast differentiation (Fig. 4D) or growth (Fig. 4E) in vitro. However, 
a modest yet significant reduction in bone nodule formation was detected in human Saos-2 cultures after 12 days 
of continuous exposure to conditioned medium from the osteotropic MDA-231-BT cells overexpressing TRAF2 
when compared to control (Fig. 4F,G).
TRAF2 regulates the behaviour of osteotropic breast cancer cells by engaging IKKβ and 
IKKε. Previous studies have shown that TRAF2-driven NFκB activation in breast cancer cells is primarily 
mediated by the expression and kinase activity of IKKβ and IKKε3,6,7,29. In view of this, we knocked down IKKβ 
and IKKε in the osteotropic MDA-231-BT cells overexpressing TRAF2 (Fig. S2) and we investigated the effects of 
these changes on these cells metastatic and osteolytic behaviour in vitro. As shown in Fig. 5, knockdown of IKKβ 
or IKKε in TRAF2 overexpressing osteotropic MDA-231-BT cells significantly inhibited cell migration (Fig. 5A 
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and C) and reduced the ability of these cells to enhance RANKL-induced osteoclast formation in bone marrow 
cultures (Fig. 5D–F). Knockdown of IKKβ or IKKε expression had no effect on the growth of MDA-231-BT cells 
overexpressing TRAF2 (Fig. 5B).
Discussion
TRAF2 has diverse functions in inflammation3,29,30, and its upregulation in mammary epithelial cells enhances 
their oncogenic transformation and promotes tumour growth7. In addition, TRAF2, through its interaction with 
NFκB, is implicated in the regulation of bone cell differentiation and bone remodelling2,4,25–27,31–33. Nonetheless, 
the contribution of TRAF2 to bone metastasis, skeletal tumour growth and osteolysis associated with advanced 
breast cancer has not been investigated. Our present in vivo, ex vivo and in vitro investigation showed that TRAF2 
overexpression in parental and osteotropic sub-clones of MDA-231 human breast cancer cells increased tumour 
cell growth and motility, whereas its knockdown is inhibitory. TRAF2 overexpression also enhanced the ability of 
osteotropic breast cancer cells and their derived factors to induce osteoclast formation, inhibit osteoblast differ-
entiation and to cause osteolysis by a mechanism that depends at least in part on NFκB activation.
Figure 1. TRAF2 enhances breast cancer tumour cell growth in vitro and in vivo. (A,B) In vitro cell migration 
of parental human MDA-231 (MDA-P) cells overexpressing (MDA-P-T2OE) and deficient (MDA-P-T2KD1 and 
T2KD2) in TRAF2 or their control (MDA-mock) after 6 hours as assessed by wound healing assay. Representative 
photomicrographs from the experiment described are shown in panel B. (C,D) In vitro cell invasion of 
parental MDA overexpressing TRAF2 (MDA-P-T2OE) cells or their control (MDA-Pmock). Representative 
photomicrographs from the experiment described are shown in panel D. (E) In vitro cell viability of parental 
human MDA-P cells overexpressing (MDA-P-T2OE) and deficient (MDA-P-T2KD1 and T2KD2) in TRAF2 or their 
control (MDA-mock) after 48 hours as assessed by AlamarBlue assays. (F) Graphic representation of orthotropic 
injection of parental human MDA-231 overexpressing TRAF2 cells into the mammary fat pads of adult mice 
(n = 7, 55 days). (G) In vivo tumour growth from the experiment described in panel F. (H) Percentage bone 
metastases from the experiment described in panel F. **p < 0.01.
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Malignant breast cancer cells accumulate oncogenic alterations that significantly affect their growth in the 
primary site and metastatic activity at distant sites such as bone34,35. The majority of studies thus far implicate 
the TRAF2/NFκB pathway in these processes were limited to the role of TRAF2 in mammary tumour gro
wth6,10,12,17,19,21–23. Here, and in broad agreement with these reports, we have found that TRAF2 overexpression 
promoted both mammary and skeletal tumour growth in mice after orthotopic and intra-tibial injections. NFκB 
signalling in breast cancer cells facilitates tumour growth and spread through induction of inflammatory medi-
ators36. In vitro examination of the metastatic behavior of parental and osteotropic cells confirmed that TRAF2 
overexpression is linked to increased tumour cell motility and invasion, whereas knockdown of TRAF2 was 
inhibitory. Examination of the levels of secreted proteins in conditioned medium from these cultures revealed 
that TRAF2 overexpression in osteotropic cells is associated with elevated levels of various pro-tumour and 
pro-migratory factors including uPAR, VEGF, IL-1, TSP-1 and Serpine 1, each with functions that enable primary 
and metastatic breast cancer cells to spread (Table S1).
Bone metastasis in advanced breast cancer is predominantly osteolytic37. Malignant breast cancer cells in bone 
acquire new characteristics influenced by matrix-derived factors24,37–40. In the present study, we provide evidence 
to support the notion that cancer-specific TRAF2 contributes to breast cancer cell behavior in bone. The evidence 
for this comes from the experiments that showed that (A) TRAF2 is highly expressed in the osteotropic MDA-
231-BT cells when compared to parental control, (B) knockdown of TRAF2 in osteotropic MDA-231-BT inhib-
ited cell migration and reduced the ability of these cells to enhance osteoclastogenesis, (C) conditioned medium 
from osteotropic MDA-231-BT overexpressing TRAF2 reduced osteoblast ability to form bone nodules in vitro, 
and (D) upregulation of TRAF2 worsened breast cancer-induced osteolysis. Microarray analysis of secreted pro-
teins in conditioned medium from osteotropic MDA-231-BT overexpressing TRAF2 indicates that these effects 
were likely due to increase in the level of tumour-derived NFκB-mediated osteolytic factors, such as TNFα, IL-1, 
granulate macrophage colony stimulating factor (GM-CSF), M-CSF, CD40L, IL-17, IL-11, vascular endothe-
lial growth factor (VEGF) (Table S1). TRAF2 overexpression also enhanced the level of tumour-derived TNFα, 
a known an inhibitory factor of osteoblast survival and differentiation4,25,33. Thus, it is reasonable to speculate 
Figure 2. TRAF2 enhances skeletal tumour growth and osteolysis in mice. (A) Graphic representation of 
intra-tibial injection of the osteotropic human MDA-231-BT overexpressing TRAF2 (MDA-BT-T2OE) cells 
or their control (MDA-BT mock) (n = 7, 14 days) in adult BALB/c‐nu/nu athymic mice. (B) In vivo tumour 
area in bone (% tissue area) from the experiment described in panel A. (C) Representative microCT scans of 
tibial metaphysis of mice from the experiment described in panel A. (D) In vivo trabecular bone volume (BV/
TV, %), Trabecular number (Tb. N, 1/μm), Trabecular thickness (Tb.Th, μm), Trabecular separation (Tb.Sp, 
μm), Trabecular pattern factor (Tb.Pf, 1/μm) and structure model index (SMI) in tibial metaphysis from the 
experiment described in panel A. (E) In vivo cortical porosity (Pot(tot), %) from the experiment described in 
panel A. *p < 0.05, **p < 0.01.
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that TRAF2 in osteotropic breast cancer cells orchestrates the expression of a set of tumour-derived factors that 
function cooperatively to alter the balance between osteoblasts and osteoclasts. Nevertheless, it is important to 
note that we cannot exclude the role of well-established systemic and bone-derived osteolytic mediators such as 
RANKL, insulin growth factor 1 (IGF-1) and parathyroid hormone-related protein (PTHrP) in TRAF2-induced 
osteolysis in our models.
A number of studies have shown that TRAF2 oncogenic activity in parental breast cancer cells is driven by 
IKKβ and IKKε3,6,7,29,41. In the skeleton, selective inhibition of IKKε or IKKβ have been found to inhibit osteoclas-
tic bone resorption28,42–44 and promote bone formation45,46. Here, we provided further evidence that IKKβ and 
IKKε are also implicated in TRAF2-driven metastatic and osteolytic behavior of the osteotropic MDA-231-BT 
cells. To this end, we showed that selective silencing of either IKKβ or IKKε reduced the ability of TRAF2 over-
expressing MDA-231-BT cells to migrate and to enhance RANKL-induced osteoclastogenesis. Altogether, these 
results demonstrate that TRAF2 contributes to breast cancer related osteolysis through its regulation of both the 
canonical and non-canonical NFκB signalling pathway.
In conclusion, our studies showed that the TRAF2/IKK/NFκB axis in osteotropic breast cancer cells contrib-
utes to breast cancer associated osteolytic bone damage. We also confirmed that cancer-specific expression of 
TRAF2 regulates mammary tumour growth and showed for the first time that TRAF2 is implicated in skeletal 
tumour burden. When combined with previous studies that demonstrated that TRAF2 plays an important role 
in breast cancer initiation3,6,7,29, our present findings indicate that targeting of TRAF2 may have a potential ther-
apeutic value in halting breast cancer metastasis and protecting the skeleton from the osteolysis associated with 
advanced breast cancer.
Figure 3. TRAF2 enhances level of tumour-derived osteolytic factors. (A) Graphic representation of 
supracalvarial injection of conditioned medium (CM) from the osteotropic human MDA-231 overexpressing 
TRAF2 (MDA-BT-T2OE) cells or their control (MDA-BT mock) (n = 7, 5 days) in immunocompetent mice. (B) In 
vivo osteolysis from the experiment described in panel A. (C) Representative microCT scans of mouse calvarial 
bone from experiment described in A. (D) Graphic representation of mouse calvarial organ co-culture system. 
(E) Ex vivo osteolysis as measured by loss of bone volume in mouse calvaria bone after exposure to conditioned 
medium (20% v/v) from the osteotropic human MDA-231 overexpressing TRAF2 (MDA-BT-T2OE) cells or 
their control (MDA-BT mock) (n = 8, 7 days). (F) Representative microCT scans of mouse calvaria bone from 
experiment described in D. (G) Osteoclast and osteoblast numbers from the experiment described in D. (H) 
Catalogue of differentially expressed inflammatory mediators in conditioned medium from mock control or 
TRAF2 overexpressing (MDA-BT-T2OE) human breast cancer cells as assessed by Proteome Profiler Human 
XL Cytokine Array Kit. (I) Venn-diagram of differentially expressed osteolytic, osteoblastic and breast cancer 
mediators in conditioned medium from the experiment described in panel G. **p < 0.01.
www.nature.com/scientificreports/
6Scientific RepoRts |  (2018) 8:39  | DOI:10.1038/s41598-017-18327-5
Figure 4. TRAF2 enhances breast cancer cell-induced bone cell activity. (A,B) In vitro osteoclastogenesis of 
murine M-CSF and RANKL stimulated bone marrow co-cultured with mock (MDA-BT mock) control, TRAF2 
overexpressing (MDA-BT-T2OE) and TRAF2 deficient (MDA-BT-T2KD) human breast cancer cells (A) or after 
exposure to conditioned medium (20% v/v) from these cells (B). (C) Representative photomicrographs of TRAcP 
positive multi-nucleated osteoclasts from the experiment described in A. (D,E) In vitro osteoblast differentiation 
(D) and viability (E) in mouse calvarial osteoblasts and the human osteoblast-like cells Saos-2 after exposure to 
conditioned medium (20% v/v) from mock (MDA-BT mock) control or TRAF2 overexpressing MDA-BT-T2OE 
human breast cancer cells for (2 days, calvarial osteoblasts, right) and (12 days, Saos-2, left) as assessed by Alkaline 
phosphatase (ALP) activity and Alamar Blue, respectively. (F) In vitro osteoblast bone nodule formation in 
cultures of the human osteoblast-like Saos-2 cells after exposure to conditioned medium (20% v/v) from mock 
(MDA-BT mock) control or TRAF2 overexpressing MDA-BT-T2OE) human breast cancer cells as assessed by 
Alazarin Red. (G) Representative photomicrographs of bone nodule in the experiment described in F. **p < 0.01.
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Methods
Materials and reagents. The parental human MDA-MB-231 (MDA-231) as representative of triple-nega-
tive breast cancer cells and human osteoblast-like cells Saos-2 were purchased from ATCC (Manassas, VA). The 
osteotropic MDA-231-BT1 was generated by repeated passages in vivo and validated for their ability to colonize 
bone and to cause osteolysis47. Tissue culture medium (DMEM and alpha-MEM) was obtained Sigma-Aldrich 
(Dorset, UK). All primary antibodies were purchased from Cell Signalling Biotechnology (MA, USA) except 
rabbit anti-actin was obtained from Sigma-Aldrich (Dorset, UK). Mouse macrophage colony stimulating factor 
(M-CSF) was obtained from R&D Systems (Abingdon, UK) and receptor activator of NFκB ligand (RANKL) was 
a gift from Patrick Mollat (Galapagos SASU, France).
Generation of stable cell lines. TRAF2 was overexpressed in human parental MDA-231 and osteo-
tropic MDA-231-BT breast cancer cells using the retroviral gene delivery system. The TRAF2 constructs used 
were a gift from the Wilkinson Lab at the Edinburgh Cancer Research UK Centre (University of Edinburgh). 
The Gateway donor vector TRAF2 from pDONR223 was recombined into Gateway destination vector 
MSCV-N-Flag-HA-IRES-PURO by LTR recombination (Behrends et al., 2010). MSCV-N-Flag-HA-IRES-PURO 
vector alone (Empty vector-MOCK) was used as the control. EGFP-MSCV-N-Flag-HA-IRES-PURO construct 
(EGFP) was used as a control to determine the transfection efficiency. HEK293ET cells were exposed to transfec-
tion mixture (5 μg of vector DNA, 5 μg of gag and pol, 5 μg of pMD2.G, 40 μl of Polyethylenimine (PEI) transfec-
tion reagent and 450 μl of standard DMEM supplemented with 10% FCS). MDA-231 and MDA-231-BT cells were 
infected using an infection mixture containing 14 μl of Polybrene transfection reagent, 5 ml of harvested virus and 
9 ml of medium was prepared and filtered (Percentage of virus 5/14*100 = 35.7%). EGFP construct transfected 
cells were used to estimate the transfection efficiency.
Small RNA interference. Parental and osteotropic MDA-231 cells were transfected with siRNA (25 nM) 
using Dharmafect 1 reagent (Dharmacon, CO, USA), according to the manufacturer’s instructions. Small inter-
fering RNAs (siRNA; siGenome SMART pool) as a pool of four annealed double-stranded RNA oligonucleotides 
for IKKβ (M-003503-03), IKKε (M-003723-02), TRAF2 (M-005198-00-0005), and non-targeting control no. 3 
(D-001210-03-05) were used according to the manufacturer’s instructions. For transfections involving the combi-
nation of TRAF2 and IKKβ oligonucleotide, each oligonucleotide was transfected at a concentration of 50 nM, so 
the total siRNA concentration is 100 nM. The cells were cultured for 48 hours in antibiotic free complete medium 
Figure 5. TRAF2 regulates osteolytic behaviour of osteotropic MDA-231-BT cells by engaging IKKβ and 
IKKε. (A) In vitro cell migration of the osteotropic human MDA-231-BT overexpressing TRAF2 (MDA-BT-
T2OE) cells or their control (MDA-BT mock) transfected with control (mock), IKKε (IKKεΚD) or IKKβ (IKKβΚD) 
siRNA. (B) In vitro cell growth of the osteotropic human MDA-BT-T2OE cells or their control MDA-BT mock 
from the experiment described in panel A. (c) Representative photomicrographs from the experiment described 
in panels A-B. (D,E) In vitro osteoclastogenesis of murine M-CSF and RANKL stimulated bone marrow after 
exposure to the osteotropic human MDA-231-BT overexpressing TRAF2 (MDA-BT-T2OE) cells or their control 
(MDA-BTmock) transfected with control (mock), IKKε (IKKεΚD) or IKKβ (IKKβΚD) siRNA (D) or conditioned 
medium (20% v/v, e) from these cells. (F) Representative photomicrographs of TRAcP positive multi-nucleated 
osteoclasts from the experiment described in panel E. *p < 0.05, **p < 0.01.
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with the transfection reagent. The efficiency of TRAF2, IKKε and IKKβ knockdown and overexpression was 
assessed by Western blot analysis.
Animal experiments. All experimental protocols were approved by the Ethics Committee at the University 
of Edinburgh (Scotland, United Kingdom) and L’Aquila (Italy) and were conducted in accordance with the United 
Kingdom Home Office regulations.
Intra-tibial injection in mice. The effect of TRAF2 overexpression on skeletal tumour growth and 
local osteolysis was studied by intra-tibial injection of osteotropic MDA-MB-231 (MDA-231-BT) breast can-
cer cell-line in 4-week-old female Balb/c nu/nu mice. Briefly, mice were divided into two groups and received 
intra-tibial injection of human breast cancer cells mock (MDA-231-BT mock) or cells overexpressing TRAF2 
(MDA-231-BT-T2OE) (5 × 104 cells) in the left leg or a sham injection of Phosphate buffered saline (PBS) into the 
right leg. Animals were euthanized 14 days post injection and bones were analyzed by micro–computed tomog-
raphy (microCT, Skyscan 1172 scanner)48. Skeletal tumor growth was measured on 2D microCT images using 
Brucker ctAN and Image J (1.34 s; NIH, Bethesda, MD, USA) and results were expressed as a percentage of total 
metaphyseal area.
Supracalvarial injection in mice. The effects of TRAF2 overexpression on breast cancer-induced osteol-
ysis was studied by supracalvarial injection of conditioned medium in immuno-competent 3-week-old C57Bl/6 
female mice. Mice were injected subcutaneously over the calvarial bones with conditioned medium (50μL) from 
human mock (MDA-231-BT mock) or cells overexpressing TRAF2 (MDA-231-BT-T2OE) breast cancer cells on 5 
consecutive days. The calvarial bone was assessed using microCT at a resolution of 8μm48.
Bone organ culture system. Ex vivo osteolysis was studied in mouse calvarial bone using an adaptation of 
the mouse calvarial organ culture49. Mouse calvarias were isolated from 7-day-old mice, divided into equal halves 
and cultured on stainless steel rafts in MDA-BT-mock or MDA-BT-T2OE conditioned medium (20% v/v). Tissue 
culture medium was refreshed every 48 hours and the cultures were terminated after 7 days. Bone volume was 
assessed by microCT (resolution, 5μm) as previously described48. Bone histomorphometry was performed on the 
calvarial bone and Hematoxilin and Eosin staining was used to evaluate osteoclasts and toluidine blue staining 
for osteoblasts. Histological sections were analysed using software based on the Aphelion Image Analysis tool kit 
(Adcis, He0rouville- Saint-Clair, France).
Osteoblast cultures. Primary osteoblasts were isolated from the calvarial bones of 2-day-old mice50. 
Primary calvarial osteoblasts (15 × 103 cells/well) and the osteoblast-like cells Saos-2 (10 × 105 cells/well) were 
cultured in standard alpha-MEM or DMEM respectively, supplemented β-glycerol phosphate (10 μM) and 
L-ascorbic acid (50 µg/ml) for 2 (osteoblast differentiation), 12 (bone nodule, Saos-2) or 21 (bone nodule, cal-
varial osteoblasts) days. Osteoblast cell number, differentiation and bone nodule formation were determined by 
AlamarBlue assay, alkaline phosphatase (ALP) assay and alizarin red (ALZ) staining50.
Osteoclast cultures. Osteoclast formation was studied in RANKL and M-CSF stimulated bone marrow cul-
tures. Bone marrow (BM) cells were obtained from the marrow of 3-month-old mice and M-CSF-dependent oste-
oclast precursor cells generated as previously described51. M-CSF-dependent osteoclast precursors were plated 
into 96 well plates (15 × 103 cells/well) in alpha-MEM supplemented with M-CSF (25 ng/ml) and RANKL (100 
ng/ml) for 6 hours prior addition of MDA-231 breast cancer cells (300 cells/well) or their conditioned medium 
(20% v/v). Cultures were stained for Tartrate-Resistant Acid Phosphatase (TRAcP)50.
Western Blotting. Western blot analysis was used to detect protein expression in breast cancer cells. Cells 
were lysed in a standard buffer (0.1% (w/v) Sodium dodecyl sulfate, 0.5% (w/v) sodium deoxycholate, 1% Triton 
X-100, 1 μM Ethylenediaminetetraacetic acid, 2% (v/v) protease inhibitor cocktail, 10 µM of sodium fluoride 
and 2% (v/v) phosphatase inhibitor cocktail). Protein concentration was determined using BCA assay (Pierce, 
USA). Total protein lysate (60μg) was resolved by SDS-PAGE (BioRAD, United Kingdom), immunoblotted with 
antibodies according to manufacturer’s instructions, detected using rabbit monoclonal antibodies (all at 1:1000 
dilution, cell Signalling Technology, USA) and immuno-complexes were visualised by enhanced chemilumines-
cence (Amersham, UK) on a Syngene GeneGnome imaging system. The intensity of the bands was quantified 
using GeneSnap software (Syngene, UK) and level of actin was used for normalization.
Measurement of levels of tumour-derived factors. Level of tumour-derived factors in conditioned 
medium from human MDA-231 breast cancer cells was determined by Proteome Profiler Human XL Cytokine 
Array Kit (ARY022, R&D Systems, Abingdon, UK), according to the manufacturer’s instructions.
Statistical analysis. Comparison between groups was done by analysis of variance (ANOVA) followed by 
Dunnet’s post hoc test (SPSS for Windows, version 11). A p-value value of 0.05 or below was considered statisti-
cally significant.
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